c-LEcta Accelerates Distribution of DENARASE® and Signs Sales Agreement With VWR
- Expansion of market position through cooperation with established company VWR in the life science sector
- Market potential of DENARASE® in the double-digit million-euro range
- With DENARASE®, c-LEcta enables highly efficient production processes for vaccines, cell and gene therapies and other biopharmaceuticals
LEIPZIG, Germany--(BUSINESS WIRE)-- c-LEcta, a worldwide operating biotechnology company with technological leadership in the fields of enzyme engineering and bioprocess development for regulated markets like food and pharma, strengthens the product marketing of its patented nuclease enzyme DENARASE® through a sales cooperation with VWR, a global trading company for laboratory supplies. DENARASE® offers more efficient production processes for biopharmaceuticals and has market potential in the double-digit million-euro range.
To continue its growth strategy, c-LEcta is further expanding its track record in the commercialization of its products. In addition to the recent successes in the food sector, the company is now pushing the accelerated product marketing in the pharma industry. The German industrial biotechnology expert has signed an agreement with VWR, an international laboratory supplies trading company, to sell its DENARASE® product. The product, which was mainly marketed by c-LEcta itself, will make a significant contribution to the company's sales in the current fiscal year 2018. Through the cooperation with VWR, c-LEcta is now addressing customers in the life science sector in an even more targeted manner. VWR is an important source of raw materials for these customers.
DENARASE® is a nuclease enzyme. It helps to remove genetic information carriers (nucleic acids; DNA and RNA) from the production process of biopharmaceuticals. The complete removal of nucleic acids from biopharmaceutical products is necessary to meet the high regulatory requirements for these products. The production process of the enzyme is patented. DENARASE® is currently the most efficient technology on the market for removing nucleic acids. This considerably simplifies the production process, reduces follow-up costs to a competitive level and ensures reliable availability. The manufacturing process meets the highest quality requirements of cGMP (current Good Manufacturing Practice) and thus meets the high demands of pharmaceutical manufacturers.
In the pharmaceutical industry, DENARASE® is used in multiple areas. A large share currently falls on the established vaccine market. Here c-LEcta is already active as a supplier for pharmaceutical companies. Another field for DENARASE® is the development and fabrication of components for use in cell and gene therapy. According to estimates by c-LEcta, the marketing of DENARASE® has a worldwide market potential in the double-digit million-euro range.
CEO Marc Struhalla: "With DENARASE®, we enable higher efficiencies in production processes than in conventional approaches and also set new standards in quality. In terms of price/performance ratio, we are thus offering the pharmaceutical industry a very attractive offer for optimizing their manufacturing procedures. The combination of our product innovation and VWR's access to the life science sector gives us the best prerequisites for gaining additional market share in a very dynamic market. We expect additional sales in the millions as an important contribution to our strong growth."
c-LEcta is a worldwide operating biotechnology company with technological leadership in the fields of enzyme engineering and bioprocess development for regulated markets like food and pharma. The company is located in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry partners. The company currently employs approximately 60 people.
c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.
cometis AG for c-LEcta
Phone: +49 (0) 611 - 205855 – 22
Fax: +49 (0) 611 - 205855 – 66